Optimal Bronchodilation for COPD Patients: Are All Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonists the Same?
Marc Miravitlles, Seungjae Baek, Vatsal Vithlani, Rahul Lad
Tuberc Respir Dis. 2018;81(3):198-215.   Published online 2018 Jun 19     DOI: https://doi.org/10.4046/trd.2018.0040
Citations to this article as recorded by Crossref logo
Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea
Ji-Yong Moon, Sang Hyuk Kim, Youlim Kim, Hyun Lee, Chin Kook Rhee, Seung Won Ra, Chang Youl Lee, Joo Hun Park, Yong Bum Park, Kwang Ha Yoo
Pulmonary Pharmacology & Therapeutics.2024; : 102298.     CrossRef
Lack of Clinical Control in COPD Patients Depending on the Target and the Therapeutic Option
Juan José Soler-Cataluña, Arturo Huerta, Pere Almagro, Diego González-Segura, Borja G Cosío
International Journal of Chronic Obstructive Pulmonary Disease.2023; Volume 18: 1367.     CrossRef
Real-world Safety and Efficacy of Indacaterol/Glycopyrronium in Japanese Patients with Chronic Obstructive Pulmonary Disease: A 52-week Post-marketing Surveillance
Chihiro Kato, Hajime Yoshisue, Noriko Nakamura, Takayoshi Sasajima
Internal Medicine.2022; 61(6): 789.     CrossRef
Double broncholytic combination of umeclidnium/ vilanterol in COPD therapy: issues of efficacy and safety
N. P. Knyazheskaya, E. Кh. Anaev, A. S. Belevskiy, M. A. Makarova
Meditsinskiy sovet = Medical Council.2022; 16(18): 49.     CrossRef
Clinical Control Criteria to Determine Disease Control in Patients with Severe COPD: The CLAVE Study
Juan José Soler-Cataluña, Pere Almagro, Arturo Huerta, Diego González-Segura, Borja G Cosío
International Journal of Chronic Obstructive Pulmonary Disease.2021; Volume 16: 137.     CrossRef
Comparative studies of dual bronchodilation in COPD
Mario Cazzola, Maria Gabriella Matera, Paola Rogliani, Luigino Calzetta
Monaldi Archives for Chest Disease.2021;[Epub]     CrossRef
Updated view on the treatment of chronic obstructive pulmonary disease in Korea
Deog Kyeom Kim, Chin Kook Rhee
Journal of the Korean Medical Association.2021; 64(3): 225.     CrossRef
Comparison of Effectiveness Using Different Dual Bronchodilator Agents in Chronic Obstructive Pulmonary Disease Treatment
Shih-Lung Cheng
Journal of Clinical Medicine.2021; 10(12): 2649.     CrossRef
Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long‐acting bronchodilator‐naïve COPD patients: A pooled analysis
Shigeo Muro, Hajime Yoshisue, Konstantinos Kostikas, Petter Olsson, Pritam Gupta, Jadwiga A. Wedzicha
Respirology.2020; 25(4): 393.     CrossRef
The concept of chronic obstructive pulmonary disease clinical control as a decision - making tool in real clinical practice for optimizing of basic pharmacotherapy
S N Avdeev, Z R Aisanov, A S Belevsky, K M Beeh, A A Vizel, S K Zyryanov, G L Ignatova, K Kostikas, I V Leshchenko, S I Ovcharenko, A I Sinopal’nikov, O N Titova, E I Shmelev
Terapevticheskii arkhiv.2020; 92(1): 89.     CrossRef
Long-acting maintenance pharmacotherapy in chronic obstructive pulmonary disease
Eneida M. Harrison, Victor Kim
Respiratory Medicine: X.2019; 1: 100009.     CrossRef
The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects
Eric Derom, Guy G. Brusselle, Guy F. Joos
Therapeutic Advances in Respiratory Disease.2019; 13: 175346661984342.     CrossRef
Pharmacotherapy for chronic obstructive pulmonary disease
In Ae Kim, Yong Bum Park, Kwang Ha Yoo
Journal of the Korean Medical Association.2018; 61(9): 545.     CrossRef
Fixed-dose combinations of bronchodilators in the treatment of patients with COPD: problem of choice
A. I. Sinopalnikov
Medical Council.2018; (15): 96.     CrossRef